tiprankstipranks
Advertisement
Advertisement
Prime Medicine: Buy Rating Reiterated with Unchanged $5 Price Target on Emerging Clinical Catalysts in Wilson’s Disease
PremiumRatingsPrime Medicine: Buy Rating Reiterated with Unchanged $5 Price Target on Emerging Clinical Catalysts in Wilson’s Disease
28d ago
Prime Medicine reports Q4 EPS (24c), consensus (26c)
Premium
The Fly
Prime Medicine reports Q4 EPS (24c), consensus (26c)
28d ago
Prime Medicine Buy Rating Reiterated as Pipeline Advances; $6 Price Target Maintained
Premium
Ratings
Prime Medicine Buy Rating Reiterated as Pipeline Advances; $6 Price Target Maintained
1M ago
Prime Medicine resolves arbitration, clarifying PM647 development rights
PremiumCompany AnnouncementsPrime Medicine resolves arbitration, clarifying PM647 development rights
2M ago
Cathie Wood’s ARK Investment buys 206.2K shares of Prime Medicine today
Premium
The Fly
Cathie Wood’s ARK Investment buys 206.2K shares of Prime Medicine today
2M ago
CYTK, PRME, DOCS, WBD, LQDA Trending With Analysts
Premium
Weekend Updates
CYTK, PRME, DOCS, WBD, LQDA Trending With Analysts
2M ago
Prime Medicine reports Q1 EPS (28c), consensus (25c)
PremiumThe FlyPrime Medicine reports Q1 EPS (28c), consensus (25c)
4M ago
Prime Medicine management to meet with Oppenheimer
Premium
The Fly
Prime Medicine management to meet with Oppenheimer
4M ago
Prime Medicine Appoints Svetlana Makhni as New CFO
Premium
Company Announcements
Prime Medicine Appoints Svetlana Makhni as New CFO
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100